Skip to main content
. 2014 Apr 18;8(7):1231–1239. doi: 10.1016/j.molonc.2014.03.016

Figure 3.

Figure 3

Anti‐CCL2 sensitizes s.c. MES‐OV to paclitaxel but not MES‐OV/TP. A. Measurement of total body tumor burden over time for animals bearing MES‐OV GFP/luc+ tumors measured with calipers and by BLI photon counts. Animals representing the four treatment groups are shown. Normalized mean ± SEM is shown for each group. Mice were treated for 6 weeks with paclitaxel twice a week at weeks 7, 8, 9, 10, 11, 12 and 13 at 20 mg/kg, and anti‐CCL2 mAbs at 20 mg/kg twice a week for the same duration. B. Measurement of total body tumor burden over time for animals bearing MES‐OV/TP GFP/luc+ tumor cells as volumes measured with caliper and by BLI photon counts. Animals representing the three treatment groups are shown. Normalized mean ± SEM is shown for each group. Mice were treated for 6 weeks with paclitaxel twice a week at weeks 9–15 at 20 mg/kg, and anti‐CCL2 mAbs at 20 mg/kg twice a week for the same duration. Mice were euthanized when the tumor size exceeded 2 cm in larger diameter. When fewer than 4 out of 5 mice remained in the group, the curves were truncated.